Program
avatrombopag
Also written as “E5501”, “Avatrombopag” and “Avatrombopag 20 mg Oral Tablet”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 180 open or running | phase 3since Sep 13, 2011 | Feb 27, 2007 | none ahead |
| Swedish Orphan Biovitrum | 71 open or running | phase 4since Nov 11, 2020 | Oct 27, 2017 | Jun 30, 2028phase 3 · NCT07786922 |
Also a collaborator on its studies: cmic-co-ltd-japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Feb 27, 2007.
- Sep 19, 2011Phase 1 study in Purpura, Thrombocytopenic, IdiopathicEisai · NCT01437384 · 36 enrolled · United States
- Dec 6, 2012Phase 1 study in Healthy VolunteersEisai · NCT01759394 · 36 enrolled · United States
- Jan 18, 2013Phase 1 study in HealthyEisai · NCT01774773 · 15 enrolled · Japan
- Oct 24, 20132 phase 3 studies in ThrombocytopeniaEisai · NCT01976104, NCT01972529
- Jan 13, 2014Phase 1 study in ThrombocytopeniaEisai · NCT02039076 · 48 enrolled · United States
- Aug 26, 2014Phase 2 study in ThrombocytopeniaEisai · NCT02227693 · 39 enrolled · Japan
- Jun 20, 2016Phase 1 study in Healthy ParticipantsEisai · NCT02809768 · 48 enrolled · United States
- Oct 27, 2017Swedish Orphan Biovitrum's first study: phase 3 study in ThrombocytopeniaNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT03326843 · 4 enrolled · United States
- Mar 7, 2018Phase 3 study in ThrombocytopeniaSwedish Orphan Biovitrum · NCT03471078 · 122 enrolled · United States, China, Hungary and more
- Aug 14, 2020Phase 3 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT04516967 · 75 enrolled · United States, France, Germany and more
- Nov 11, 2020Phase 4 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT04638829 · 60 enrolled · United States
- Sep 8, 2021Phase 3 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT05046327
- Apr 21, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT05369208 · 19 enrolled · Japan
- Jul 30, 2026Phase 3 study in Anemia, AplasticSwedish Orphan Biovitrum · NCT07786922 · 26 planned
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Anemia, AplasticSwedish Orphan Biovitrum · NCT07786922
TargetBeta
“The maleate salt form of avatrombopag, an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, ”NCIt, by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eltrombopagrule | GlaxoSmithKline | phase 4 | 49 |
| romiplostimrule | Amgen | phase 4 | 38 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07786922Anemia, Aplastic | 3 | Not yet recruiting | Swedish Orphan Biovitrum | Jun 30, 2028 | 26 |
| NCT05369208Purpura, Thrombocytopenic, Idiopathic · Japan | 3 | Completed | Swedish Orphan Biovitrum | Jan 17, 2024 | 19 |
| NCT05046327Purpura, Thrombocytopenic, Idiopathic | 3 | Withdrawn | Swedish Orphan Biovitrum | Apr 6, 2024 | 0 |
| NCT04638829Purpura, Thrombocytopenic, Idiopathic · United States | 4 | Completed | Swedish Orphan Biovitrum | Jan 3, 2024 | 60 |
| NCT04516967Purpura, Thrombocytopenic, Idiopathic · United States, France, Germany and more | 3 | Completed | Swedish Orphan Biovitrum | Nov 8, 2023 | 75 |
| NCT03471078Thrombocytopenia · United States, China, Hungary and more | 3 | Completed | Swedish Orphan Biovitrum | Aug 28, 2020 | 122 |
| NCT03326843Thrombocytopenia · United States | 3 | Terminated | Swedish Orphan Biovitrum | Feb 25, 2019 | 4 |
| NCT02809768Healthy Participants · United States | 1 | Completed | Eisai | Aug 2016 | 48 |
| NCT02227693Thrombocytopenia · Japan | 2 | Completed | Eisai | Apr 1, 2015 | 39 |
| NCT02039076Thrombocytopenia · United States | 1 | Completed | Eisai | Jun 2014 | 48 |
| NCT01976104Thrombocytopenia · United States, Argentina, Australia and more | 3 | Completed | Eisai | Jan 30, 2017 | 204 |
| NCT01972529Thrombocytopenia · United States, Argentina, Australia and more | 3 | Completed | Eisai | Jan 26, 2017 | 231 |
| NCT01774773Healthy · Japan | 1 | Completed | Eisai | Jul 2013 | 15 |
| NCT01759394Healthy Volunteers · United States | 1 | Completed | Eisai | Jan 2013 | 36 |
| NCT01438840Purpura, Thrombocytopenic, Idiopathic · Australia, Belgium, Bulgaria and more | 3 | Completed | Eisai | Nov 2013 | 49 |
| NCT01437384Purpura, Thrombocytopenic, Idiopathic · United States | 1 | Completed | Eisai | Mar 2012 | 36 |
| NCT01433978Purpura, Thrombocytopenic, Idiopathic · United States | 3 | Terminated | Eisai | Sep 2013 | 24 |
| NCT01355289Thrombocytopenia · United States | 2 | Completed | Eisai | Feb 2014 | 65 |
| NCT01327872Purpura, Thrombocytopenic, Idiopathic · Netherlands | 1 | Completed | Eisai | Apr 2011 | 84 |
| NCT01289509Purpura, Thrombocytopenic, Idiopathic · United States | 1 | Completed | Eisai | Mar 2011 | 42 |
| NCT01260155Healthy Subjects · United States | 1 | Completed | Eisai | Jun 2010 | 16 |
| NCT01251731Healthy Subjects · United States | 1 | Completed | Eisai | Jan 2011 | 36 |
| NCT00914927Thrombocytopenia · United States | 2 | Completed | Eisai | Nov 11, 2011 | 130 |
| NCT00625443Purpura, Thrombocytopenic, Idiopathic · United States | 2 | Completed | Eisai | Jun 2009 | 53 |
| NCT00441090Purpura, Thrombocytopenic, Idiopathic · United States | 2 | Completed | Eisai | Jan 2009 | 64 |
How it is read
Names in the registry
- “E5501”, 9 entries
- “Avatrombopag”, 8 entries
- “Avatrombopag 20 mg Oral Tablet”, 2 entries
- “Avatrombopag Oral Tablet”, 2 entries
- “avatrombopag”, 2 entries
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 11 studies
- Thrombocytopenia, 8 studies
- Anemia, Aplastic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.